NasdaqGS:APYX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Apyx Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APYX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.3%

APYX

4.0%

US Medical Equipment

1.9%

US Market


1 Year Return

-25.8%

APYX

5.1%

US Medical Equipment

4.3%

US Market

Return vs Industry: APYX underperformed the US Medical Equipment industry which returned 5.1% over the past year.

Return vs Market: APYX underperformed the US Market which returned 4.3% over the past year.


Shareholder returns

APYXIndustryMarket
7 Day-4.3%4.0%1.9%
30 Day21.0%-0.6%2.7%
90 Day48.0%20.3%26.4%
1 Year-25.8%-25.8%6.1%5.1%6.5%4.3%
3 Year112.9%112.9%54.1%49.9%35.1%26.2%
5 Year134.5%134.5%106.3%90.1%67.0%48.4%

Price Volatility Vs. Market

How volatile is Apyx Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Apyx Medical undervalued compared to its fair value and its price relative to the market?

2.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APYX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APYX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APYX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: APYX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APYX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APYX is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Apyx Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-12.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APYX's revenue (39% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: APYX's revenue (39% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Apyx Medical performed over the past 5 years?

-44.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APYX is currently unprofitable.

Growing Profit Margin: APYX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of -44.1% per year.

Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).


Return on Equity

High ROE: APYX has a negative Return on Equity (-22.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Apyx Medical's financial position?


Financial Position Analysis

Short Term Liabilities: APYX's short term assets ($74.2M) exceed its short term liabilities ($10.6M).

Long Term Liabilities: APYX's short term assets ($74.2M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: APYX's debt to equity ratio (0.2%) is considered satisfactory.

Reducing Debt: APYX's debt to equity ratio has reduced from 12.8% to 0.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APYX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APYX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 42.8% each year.


Next Steps

Dividend

What is Apyx Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APYX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APYX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Charlie Goodwin (54yo)

2.58yrs

Tenure

US$1,945,258

Compensation

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves  ...


CEO Compensation Analysis

Compensation vs Market: Charlie's total compensation ($USD1.95M) is above average for companies of similar size in the US market ($USD1.34M).

Compensation vs Earnings: Charlie's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Charles Goodwin
President2.58yrsUS$1.95m0.083% $149.7k
Tara Semb
CFO, Treasurer & Secretary1.5yrsUS$700.00kno data
Moshe Citronowicz
Senior Vice President8.5yrsUS$721.36k1.19% $2.2m
Todd Hornsby
Executive Vice President1.5yrsUS$892.26kno data

2.0yrs

Average Tenure

52yo

Average Age

Experienced Management: APYX's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Charles Goodwin
President2.58yrsUS$1.95m0.083% $149.7k
Andrew Makrides
Independent Chairman of the Board6.58yrsUS$139.87k1.78% $3.2m
Michael Geraghty
Independent Director9.33yrsUS$129.87kno data
Lawrence Waldman
Lead Independent Director9.33yrsUS$218.37kno data
Gregory Konesky
Member of Scientific Advisory Boardno dataUS$9.30kno data
Yuval Carmel
Member of Scientific Advisory Boardno datano datano data
John Andres
Independent Vice-Chairman of the Board6yrsUS$157.37kno data
Minnie Baylor-Henry
Independent Director0.92yrUS$97.37kno data
Craig Swandal
Independent Director2.33yrsUS$119.87k0.13% $239.5k
Dennis Chi
Member of Medical Advisory Board3.5yrsno datano data

4.8yrs

Average Tenure

69yo

Average Age

Experienced Board: APYX's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: APYX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Apyx Medical Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Apyx Medical Corporation
  • Ticker: APYX
  • Exchange: NasdaqGS
  • Founded: 1982
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$181.176m
  • Shares outstanding: 34.18m
  • Website: https://apyxmedical.com

Number of Employees


Location

  • Apyx Medical Corporation
  • 5115 Ulmerton Road
  • Clearwater
  • Florida
  • 33760
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APYXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 1983
BOVDB (Deutsche Boerse AG)YesCommon SharesDEEURJul 1983

Biography

Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company’s Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/02 00:12
End of Day Share Price2020/07/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.